Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNMD 
Mind Medicine Inc (MNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: MNMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.91
1 Year Target Price $24.91
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 43.12% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 948.82M USD | Price to earnings Ratio - | 1Y Target Price 24.91 |
Price to earnings Ratio - | 1Y Target Price 24.91 | ||
Volume (30-day avg) 11 | Beta 3.31 | 52 Weeks Range 4.70 - 14.30 | Updated Date 10/23/2025 |
52 Weeks Range 4.70 - 14.30 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.55% | Return on Equity (TTM) -59.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 787992663 | Price to Sales(TTM) - |
Enterprise Value 787992663 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.57 | Shares Outstanding 76087943 | Shares Floating 70203301 |
Shares Outstanding 76087943 | Shares Floating 70203301 | ||
Percent Insiders 0.78 | Percent Institutions 55.73 |
Upturn AI SWOT
Mind Medicine Inc
Company Overview
History and Background
Mind Medicine (MindMed) Inc. was founded in 2019. It is a biopharmaceutical company developing psychedelic-inspired medicines and therapies to address mental health and addiction.
Core Business Areas
- Drug Development: Focuses on researching, developing, and commercializing novel psychedelic and psychedelic-inspired therapies for mental health disorders.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Technology Development: Explores digital therapeutics and technologies to enhance the delivery of mental healthcare.
Leadership and Structure
Robert Barrow is the CEO. The organizational structure includes departments for research and development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- MM-120 (LSD):: A proprietary form of LSD being developed for generalized anxiety disorder (GAD). Currently in Phase 2b clinical trials. Competitors in anxiety treatment include traditional pharmaceuticals (SSRIs, SNRIs) from companies like Pfizer and Eli Lilly, and other emerging therapies. Revenue is currently nil as MM-120 is in development.
- MM-402 (R-MDMA):: Developing an enantiomer of MDMA, R-MDMA, for the treatment of core symptoms of autism spectrum disorder (ASD). Currently in Phase 1 clinical trials. Competitors include pharmaceutical interventions targeting symptoms of ASD from companies like Janssen and Otsuka Pharmaceutical. Revenue is currently nil as MM-402 is in development.
Market Dynamics
Industry Overview
The psychedelic medicine industry is an emerging field focused on developing and commercializing psychedelic compounds for mental health conditions. It's characterized by regulatory hurdles, high research costs, and growing investor interest.
Positioning
MindMed is a prominent player in the psychedelic medicine space, focusing on LSD and MDMA-based therapies. Its competitive advantages include its clinical trial progress and intellectual property portfolio.
Total Addressable Market (TAM)
The TAM for mental health treatments is estimated to be in the tens of billions of dollars annually. MindMed is positioned to capture a portion of this market with its novel therapies. The exact TAM that can be captured will depend on regulatory approvals and clinical trials.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced leadership team
- Advanced clinical trial programs
- Focus on underserved mental health needs
Weaknesses
- Limited revenue stream (pre-commercialization)
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Regulatory uncertainties surrounding psychedelic medicines
Opportunities
- Potential for breakthrough therapies in mental health
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Growing acceptance of psychedelic medicines
Threats
- Competition from established pharmaceutical companies
- Regulatory delays and setbacks
- Negative public perception of psychedelics
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GH Research (GHRS)
- COMPASS Pathways (CMPS)
- ATAI Life Sciences (ATAI)
Competitive Landscape
MindMed competes with other companies developing psychedelic-inspired therapies. Its competitive advantages include its focus on LSD and MDMA-based treatments and its progress in clinical trials. Disadvantages include its relatively smaller size and limited financial resources compared to some competitors.
Major Acquisitions
HealthMode
- Year: 2020
- Acquisition Price (USD millions): 32.4
- Strategic Rationale: Acquisition of HealthMode to advance its digital medicine strategy for mental health.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by the progress of clinical trials and the expansion of the drug pipeline.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary significantly depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing MM-120 through Phase 2b trials and exploring new indications for its drug candidates.
Summary
MindMed is a biopharmaceutical company in the emerging psychedelic medicine space. Its success hinges on the outcomes of clinical trials and regulatory approvals for its drug candidates, particularly MM-120. The company faces risks related to competition, regulation, and financing. Positive clinical trial results would strongly benefit the company's future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment in biopharmaceutical companies is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mind Medicine Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-03-03 | CEO & Director Mr. Robert Barrow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.mindmed.co |
Full time employees 74 | Website https://www.mindmed.co | ||
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.